Efficacy of Gefitinib Combined with Methotrexate in the Medical Management of Ectopic Pregnancy

Authors

Keywords:

Ectopic Pregnancy, Gefitinib, Methotrexate, Tubal Ectopic Pregnancy, Conservative Management, β-hCG, Trophoblastic Regression, Fertility Preservation, Targeted Therapy, Medical Management

Abstract

Background:

Ectopic pregnancy is a potentially life-threatening implantation of a fertilized ovum outside the uterine cavity, accounting for significant first-trimester maternal morbidity and mortality. Methotrexate is the standard medical therapy; however, treatment failure and need for rescue surgery remain major clinical concerns.

 

Objective:

The study aims to evaluate the efficacy of gefitinib combined with methotrexate in the medical management of ectopic pregnancy.

 

Methodology:

The study analyses the efficacy of gefitinib–methotrexate combination therapy by evaluating treatment success without surgery, β-hCG decline, time to resolution, adverse effects, and need for additional intervention through clinical trials and review evidence.

 

Results:

Combination therapy demonstrated successful resolution in 86% of stable tubal ectopic pregnancies without surgical intervention. Median resolution time was reduced by nearly 34% compared with methotrexate alone, with significantly faster β-hCG decline observed during the first week of treatment. In non-tubal ectopic pregnancies, successful resolution and preservation of fertility outcomes were also reported. Common adverse effects included transient acneiform rash and diarrhea, while serious toxicities remained uncommon.

 

Conclusion:

Gefitinib combined with methotrexate represents a promising adjunctive medical therapy for ectopic pregnancy by enhancing trophoblastic regression and reducing treatment duration. The combination may improve conservative management outcomes, although further large-scale randomized trials are required to establish long-term efficacy and safety.

References

Skubisz MM, Horne AW, Johns TG, Nilsson UW, Duncan WC, Wallace EM, Critchley HOD, Tong S. Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy. Obstet Gynecol. 2013 Oct;122(4):745-751. doi: 10.1097/AOG.0b013e3182a14cfb. PMID: 24084530.

Nilsson UW, Johns TG, Wilmann T, Kaitu'u-Lino T, Whitehead C, Dimitriadis E, Menkhorst E, Saglam B, Gao Y, Greenall SA, Horne AW, Tong S. Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth. Obstet Gynecol. 2013 Oct;122(4):737-744. doi: 10.1097/AOG.0b013e3182a1ba56. Erratum in: Obstet Gynecol. 2021 May 1;137(5):962. doi: 10.1097/AOG.0000000000004380. PMID: 24084529.

Capmas P, Fernandez H. Effectiveness of gefitinib in combination with methotrexate in the treatment of ectopic pregnancy. Int J Womens Health. 2015 Jul 3;7:673-6. doi: 10.2147/IJWH.S55556. PMID: 26170723; PMCID: PMC4498725.

Tong S, Skubisz MM, Horne AW. Molecular diagnostics and therapeutics for ectopic pregnancy. Mol Hum Reprod. 2015 Feb;21(2):126-35. doi: 10.1093/molehr/gau084. Epub 2014 Sep 17. PMID: 25232044.

Italiano S, Tong S, Readman E, Tassone M, Hastie R, Pritchard N. Combination methotrexate and gefitinib: A potential medical treatment for inoperable nontubal ectopic pregnancy. J Obstet Gynaecol Res. 2020 Mar;46(3):531-535. doi: 10.1111/jog.14169. Epub 2019 Dec 9. PMID: 31814216.

Downloads

Published

2026-08-19

How to Cite

Muraleedharan, T., & Bansal, A. (2026). Efficacy of Gefitinib Combined with Methotrexate in the Medical Management of Ectopic Pregnancy. International Journal of Medical Students. Retrieved from https://ijms.pitt.edu/IJMS/article/view/4879

Issue

Forthcoming

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2026 Tanishka Muraleedharan, Anushka Bansal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org